Bacteria: Gram-negative

Citrobacter freundii

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A gut and environmental Gram-negative rod causing opportunistic infection.

Infections

Urinary tract infection, intra-abdominal infection, bloodstream infection; neonatal meningitis is described with other Citrobacter species.

Signs and symptoms

Urinary infection, the most common presentation: painful urination, frequency, urgency, cloudy or foul-smelling urine, flank pain or fever. Wound and intra-abdominal infection: pain, swelling and fever. Bloodstream infection: fever and chills.

Antibiotic and antimicrobial resistance

Chromosomal AmpC (AmpC); can acquire carbapenemases (carbapenemases).

Treatment considerations

Guided by susceptibility testing. C. freundii carries an inducible chromosomal AmpC, so third-generation cephalosporins can fail during treatment; IDSA guidance suggests cefepime for serious infection, with a carbapenem when cefepime is not suitable.

Rod-shaped Citrobacter freundii bacteria, scanning electron micrograph
Citrobacter freundii, scanning electron micrograph. CDC; public domain. Image source
Gram-negative rods, schematic
Gram-negative rods. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Healthcare-associated infections: diseases and organisms.
  2. CDC. ESBL-producing Enterobacterales.
  3. CDC. Carbapenem-resistant Enterobacterales (CRE).
  4. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
  5. IDSA. Complicated Urinary Tract Infections guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.